Quintrio
Home

Stock overview

Belite Bio, Inc American Depositary Shares

BLTE

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Last trade $159.91
Day change -$2.65 (-1.63%)
Day range $156.52 – $163.71
Volume 58,092
Market cap $6.55B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for BLTE.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for BLTE.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Belite Bio Announces Uplisting to the Nasdaq Global Select Market

Belite Bio, Inc. (NASDAQ: BLTE) announced its uplisting from the Nasdaq Capital Market to the Nasdaq Global Select Market, effective October 19, 2026. The company, a clinical-stage drug developer focused on retinal diseases, achieved this milestone by meeting the higher financial and liquidity standards required. The uplisting is expected to enhance visibility among institutional investors, improve liquidity, and broaden market recognition as the company continues advancing tinlarebant, its lead candidate for Stargardt disease treatment.

GlobeNewswire Inc.

Belite Bio to Host Virtual Commercial Day on September 2, 2026

Belite Bio announced that the FDA accepted and granted Priority Review designation for its New Drug Application for tinlarebant to treat Stargardt disease type 1 (STGD1), with a decision date set for February 12, 2027. The company will host a Virtual Commercial Day on September 2, 2026, to discuss the drug's commercial opportunity and prelaunch preparedness strategies.

GlobeNewswire Inc.

Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium

Belite Bio, a clinical-stage drug development company, announced it will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Investor Symposium on July 9, 2026. The company is advancing tinlarebant, an oral therapy for degenerative retinal diseases including Stargardt disease type 1 and geographic atrophy, with completed Phase 3 trials and ongoing Phase 2/3 and Phase 3 trials.

GlobeNewswire Inc.

Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1

Belite Bio announced the completion of its rolling NDA submission to the FDA for tinlarebant, an oral therapy for Stargardt disease type 1 (STGD1), a rare inherited retinal disease affecting approximately 53,000 people in the U.S. with no current approved treatments. The submission was made under Breakthrough Therapy Designation and will undergo a 60-day FDA review period. The Phase 3 DRAGON trial demonstrated tinlarebant's ability to significantly reduce the growth rate of retinal lesions compared to placebo.

GlobeNewswire Inc.

Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update

Belite Bio initiated a rolling NDA submission to the FDA for tinlarebant to treat Stargardt disease type 1 (STGD1), with completion expected in Q2 2026. The company reported Q1 2026 results showing $798.6 million in cash and investments, increased R&D and SG&A expenses due to commercialization preparation and team expansion, and a net loss of $26.9 million (GAAP). Key commercial leadership positions have been hired as the company prepares for potential market launch.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.